Shares of Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) shot up 11.4% during mid-day trading on Thursday . The stock traded as high as $0.90 and last traded at $0.88, 250,897 shares changed hands during trading. A decline of 4% from the average session volume of 261,665 shares. The stock had previously closed at $0.79.
Several brokerages have issued reports on SNNA. ValuEngine raised Sienna Biopharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday. JPMorgan Chase & Co. lowered Sienna Biopharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Monday, May 13th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $21.67.
The company has a debt-to-equity ratio of 0.90, a current ratio of 2.61 and a quick ratio of 2.61. The business has a 50 day moving average price of $0.88.
Sienna Biopharmaceuticals (NASDAQ:SNNA) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.67) earnings per share (EPS) for the quarter. As a group, equities analysts predict that Sienna Biopharmaceuticals Inc will post -1.93 earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the business. Dimensional Fund Advisors LP bought a new stake in Sienna Biopharmaceuticals during the fourth quarter worth about $36,000. LLBH Private Wealth Management LLC purchased a new stake in Sienna Biopharmaceuticals during the 1st quarter valued at about $49,000. Raymond James & Associates purchased a new stake in Sienna Biopharmaceuticals during the 4th quarter valued at about $54,000. Two Sigma Investments LP purchased a new stake in Sienna Biopharmaceuticals during the 4th quarter valued at about $149,000. Finally, Deutsche Bank AG grew its stake in Sienna Biopharmaceuticals by 242.1% during the 4th quarter. Deutsche Bank AG now owns 104,718 shares of the company’s stock valued at $241,000 after acquiring an additional 74,104 shares in the last quarter. 51.32% of the stock is owned by hedge funds and other institutional investors.
About Sienna Biopharmaceuticals (NASDAQ:SNNA)
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
Read More: Conference Calls and Individual Investors
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.